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between lnTGF-b levels and age or BMI, and no signiﬁcant interactions
by race or gender were identiﬁed. No signiﬁcant differences were seen
for mean serum lnTGF-b levels by rOA status at the knee or the hip
in unadjusted or adjusted analyses (Table). There was a trend toward
increasing mean lnTGF-b with increasing severity at the knee in the
unadjusted analyses (p = 0.080) that was attenuated after adjustment
(p = 0.188). There was no association between lnTGF-b levels and unilat-
eral compared to bilateral knee or hip rOA in either unadjusted or adjusted
analyses.
Table: Least squared means of lnTGF-b by rOA outcome
Outcome Unadjusted
Mean
95%CI p value Adjusted
Mean
95%CI p value
HOA absent 2.80 2.76−2.85 0.713 2.80 2.76−2.85 0.862
HOA present 2.82 2.74−2.90 2.81 2.73−2.89
KOA absent 2.79 2.74−2.85 0.185 2.80 2.74−2.85 0.352
KOA present 2.84 2.79−2.89 2.83 2.78−2.88
KOA severity:
No KOA 2.79 2.74−2.85 n/a 2.79 2.74−2.85 n/a
Mild KOA 2.83 2.77−2.88 0.417* 2.82 2.76−2.88 0.505*
Mod/severe KOA 2.90 2.80−3.00 0.080* 2.88 2.77−2.99 0.188*
*p for comparison to no OA.
Conclusions: Although serum TGF-b was increased in AA compared
to Whites and in women compared to men, there were no signiﬁcant
associations with presence, laterality, or severity of knee or hip rOA,
suggesting that serum TGF-b is unlikely to be useful as a stand-alone
biomarker in OA studies.
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Purpose: Erosive osteoarthritis of the hand (EHOA) is thought to be an
aggressive variant of hand OA characterised by prominent local inﬂamma-
tion and radiographic aspects of bone erosions in interphalangeal joints.
Although serum levels of ultrasensitive CRP were found to be higher in
patients with EHOA in comparison with those with non-EHOA, biomarkers
have not been investigated until now in these patients.
Aims: (1) To determine Coll2−1, Coll2−1NO2 and myeloperoxydase
(MPO) levels in serum of patients with EHOA and compare these levels
with those of non-EHOA; (2) To investigate relationships between these
biomarkers and disease indices of severity and activity in EHOA.
Methods: Coll2−1, Coll2−1NO2 and MPO were measured in 82 patients,
62 with EHOA (57F and 5M, median age 59.5, range 41−74 years) and
20 with non-EHOA (all F, median age 55, range 43−73 years), fulﬁlling
ACR criteria for hand OA. EHOA was deﬁned in the presence of at least
one central bone erosion in the interphalangeal joints. Patients were also
evaluated for disease duration, number of affected (swollen or deformed)
joints, number of clinically active (swollen and painful or tender) (NCAJ),
radiographic score (RS), and number of active joints at bone scintigraphy
(NSAJ).
Results: Serum levels of Coll2−1NO2 and MPO were higher in patients
with EHOA (0.48±0.63 nM and 231.9±119.8 ng/ml, respectively) than in
those with non-EHOA (0.23±1.13 nM, p 0.067), although a signiﬁcance
was only reached by MPO (160.15± ng/ml, p< 0.043). No difference
was observed between the two groups for serum levels of Coll2−1. No
correlations were observed between the substances considered and the
other indices of disease activity or severity.
Conclusions: This is the ﬁrst study demonstrating an increase of
some serum biomarkers in EOA. In this context the most interesting
biomarker is MPO, although a trend for an elevation was also observed
for Coll2−1NO2.
99 A SENSITIVE AGGRECANASE ASSAY FOR
IN-VITRO/CELLULAR ACTIVITIES AND FOR TESTING
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Purpose: The loss of cartilage matrix in osteoarthritis (OA) is character-
ized by increased loss of type II collagen and aggrecan by collagenases
and aggrecanases, respectively. Depletion of aggrecan is an early and an
important event in OA. We have observed ongoing aggrecanase activity
in late stage human osteoarthritic cartilage. Inhibition of aggrecanase
activity and upstream effectors may offer an attractive therapeutic target
for OA. Methods to detect and quantify aggrecanase activity for OA target
identiﬁcation/validation, screening of compounds, and to test activity
in biological/clinical samples is gaining great importance. A sensitive
aggrecanase ELISA has been developed to detect pM levels of both in-
vitro as well as cellular aggrecanase activities.
Methods: Either of two custom-made, C-terminal biotinylated, ‘aggre-
canase cleavage site’ (G373-374A) containing aggrecan interglobular do-
main (IGD) peptides (51/58mer) was used as the substrate. Samples
with or without inhibitors were added to the peptide-coated plate and
incubated. Cleaved aggrecan was detected by HRP-BC3 (anti-ARGS),
aggrecanase activity quantiﬁed, and IC50 determined. The assay was
also used to measure aggrecanase activity in synovial ﬂuid samples of
rats where the animals were oral dosed with drug and knee synovial ﬂuid
samples collected after intra-articular injection of aggrecanase. For the
cell-based assay format, primary bovine chodrocytes were cultured onto
peptide-coated plates followed by Il-1a induction with or without inhibitors.
Cellular activity was measured both in cell extracts and in conditioned
media to study the efﬁcacy of inhibitors.
Results: The in-vitro/cell-based 96-well format aggrecanase activity as-
say was found to be very selective and sensitive (detection range of
0.01−1 nM aggrecanase). IC50 values of aggrecanase inhibitors tested
in the ELISA were comparable to the FRET IC50s. The ELISA used
70−75 fold less enzyme than the FRET assay. IC50 determination was
not limited at low nM ranges in the ELISA as compared to the FRET
that could not determine IC50s below 30nM. The assay detected intra-
articularly injected aggrecanase activity in the diluted knee synovial ﬂuid
samples of rats dosed with drug and determined the inhibitory level
reﬂecting in-vivo drug efﬁcacy. In the cell-based assay format, primary
bovine chondrocytes produced aggrecanase activity upon Il-1 induction.
This activity was detected in the assay enabling a higher-throughput cell
based screening of aggrecanase inhibitors as compared to bovine explant
cultures.
Conclusions: The sensitive in-vitro/cellular aggrecanase activity ELISA
uses a longer IGD peptide of aggrecan that better represents the bio-
logical substrate as compared to the FRET peptide (10mer). This assay
is more sensitive as compared to the FRET and could determine IC50s
at low nM levels. The cell-based format of the assay would be useful for
chondrocyte-based secondary screening of aggrecanase inhibitors at a
higher throughput. This can also be extended to other purposes including
identiﬁcation/validation of OA targets (example: aggrecanase activity in
response to knockdown/over expression of potential OA targets in primary
human chondrocytes). Thus, the assay has the added advantage of
detecting cellular activity that would not be possible with the existing
commercial aggrecanase activity assays. The assay has been used
to monitor in-vivo drug efﬁcacy in animal models. The application of
this assay to detect activity in human synovial ﬂuids is currently being
evaluated.
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Purpose: To identify biochemical markers that predict OA progression.
Such prognostic biomarkers could provide valuable inclusion criteria for
clinical efﬁcacy trials to decrease the variability within patient populations
as well as to decrease the time required to detect a signiﬁcant change
in the outcome in response to treatment. We studied the relationship
between several biochemical markers and radiographic joint space nar-
rowing (JSN) (i.e., change in joint space width (JSW)) in OA patients over
2 years.
Methods: Urine, serum, and plasma samples were collected at 5 visits:
0, 3, 6, 12, and 24 months from healthy (n = 85) and OA human subjects
with symptomatic knee OA (n = 75). The diagnosis of OA was based on
a combination of pain or stiffness on most days of a month during the
past year and the presence of radiographic OA as deﬁned by Kellgren
and Lawrence grades (KLG) 0, 1, 2 and 3. Knee radiographs were
taken using the Lyon-Schuss protocol at 0 (baseline), 12, and 24 month.
Samples were analyzed for the levels of cartilage, bone, and synovium
matrix degradation and synthesis markers as well as for markers of
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inﬂammation. The following biomarkers were measured for all 5 visits:
Serum: sCOMP, sCTXI, sIntactPINP, sPIIANP, sCPII, sPIIINP.
Plasma: p15HETE, pNPII, pPGE2, pYNO2.
Urine: uAgg, uCTXII, uTINE, uTIINE, uTIIINE, uOsteop.
A simple linear regression model was produced for each biomarker
against JSN after 24 months. Multiple test comparisons were adjusted for
through use of false discovery rate methods, a=0.1. Multivariate linear
regression models examining all biomarkers against change in JSW were
generated using forward and backward stepwise regression algorithms.
These algorithms were used to reduce the number of biomarkers included
in the ﬁnal model by including signiﬁcant or removing non-signiﬁcant
variables from the model. All of the individual biomarkers data showed
skewed distributions; thus a log-transformation of the data was used.
Results: Quality data was generated for 16 individual biomarkers for
160 subjects at 5 time points during 2-year longitudinal OA method
study. Several approaches to analyze these data for the identiﬁcation
of biochemical markers that predict JSN at 24 month were undertaken.
The most straightforward approach was to use the baseline (BL) levels
of each individual biomarker. Another approach was to evaluate changes
in biochemical markers over a short period of time (3−6 months). Finally,
multivariate analysis of all 16 biomarkers at baseline was investigated
since a combination of multiple biomarkers may help explain disease
behaviour better than an individual biomarker. Preliminary data using
all subjects indicated that levels of the urinary biomarker, uTIINE, at
baseline correlate to JSN at 24 month with a p value of 0.0071. A subset
of subjects (KLG3 and KLG2) showing the most signiﬁcant changes
in JSN was evaluated separately. For this rapidly progressing subset,
among all 16 biomarkers, baseline data of uTINE, uTIIINE, and uOsteop
correlated to JSN at 24 month with p values of 0.0340, 0.0297, and
0.0120, respectively.
Conclusions: Based on this longitudinal OA clinical methods study,
biochemical biomarkers show signiﬁcant promise with regard to their
prediction in radiographic JSN at 24 months.
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Purpose: Efﬁcient and reproducible segmentation of knee cartilage is
necessary for quantiﬁcation and analysis of cartilages from large co-
horts of osteoarthritis subjects such as in the OAI database. We have
developed and implemented a semi-automated cartilage segmentation
method using a graph-cuts algorithm. The purpose of this study was
to evaluate and compare, between the semi-automated and manual
delineation methods, the efﬁciency and reproducibility for segmenting
knee cartilages.
Methods: Nine right knee MR image sets of varying severities of OA
[Kellgren-Lawrence (KL) grade] were selected from the sagittal double-
echo steady-state (DESS) MR images in the OAI-0.B.1 Imaging Data
Set (Siemens 3.0T Trio, 160 slices with 0.7mm thickness): one set with
KL 0; 3 with KL 1; 3 with KL 2; and 2 with KL 3. Two radiologist
readers (1 and 2) segmented the knee cartilage on ‘every third’ slice
by manual boundary delineation (M method: M1 and M2). Segmentation
was repeated by both readers using the semi-automated method, which
was based on a graph-cuts algorithm (SA method: SA1 and SA2). The
SA method incorporates the seeds speciﬁed by a reader and intensity
values to compute the optimal segmentation. Seed speciﬁcation and
computation were iterated allowing the reader to edit and improve the
segmentation results. The efﬁciency in segmentation was measured in
terms of segmentation processing time used by readers. The inter-reader
reproducibility in segmentation was determined by superimposing the
segmented cartilages (M1 onto M2 or SA1 onto SA2) and computing
the Dice Similarity Coefﬁcient (DSC: ratio of overlapped volume/mean
volume) as an index of matching between the segmented cartilages.
Perfect match corresponds to 100% DSC. In addition, the inter-method
reproducibility of a reader was measured by computing DSC’s of (SA1
onto M1) and (SA2 onto M2).
Results: The manual segmentation processing time (mean±SD, min)
was (160±45) for M1 and (121±27) for M2. On the other hand, the
SA processing time, which was based on ‘every’ slice, was (54±14)
for SA1 and (33±6) for SA2, indicating that the SA method was sig-
niﬁcantly more efﬁcient than the manual method (p< 0.001). The inter-
reader reproducibility of each method measured by DSC (mean±SD)
was 94.2±1.5% (SA1 onto SA2) and 87.7±1.3% (M1 onto M2), indicating
that the semi-automated method was signiﬁcantly higher in inter-reader
reproducibility than the manual method (p< 0.001). Finally, the inter-
method reproducibility of a reader also measured by DSC was 87.4±1.6%
(SA1 onto M1) for reader 1 and 87.7±1.2% (SA2 onto M2) for reader 2,
which supports the feasibility of the SA method as an alternative to a
manual delineation method.
Conclusions: We have developed and implemented a semi-automated
cartilage segmentation method based on a graph-cuts algorithm which
permitted us to segment the knee cartilages from high-resolution MR
images with signiﬁcantly higher (approximately 10 times) efﬁciency and
reproducibility than a manual boundary delineation segmentation method.
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Purpose: Degradation of the core aggrecan protein is a complicated
process of aggrecanase and MMP activity, resulting in a long range of
identiﬁed degradation products, albeit with less understanding of their
individual biological role and release from the matrix. The aggrecan
molecule is linked via the G1 domain and the LINK protein to hyaluronic
acid. As a consequence of this molecular interaction with the ECM,
some proteolytic fragments of aggrecan may be released from the matrix
whereas others are primarily retained.
The aim of this study was to proﬁle two fragments of aggrecanase medi-
ated aggrecan degradation, i.e. the 374’ARGSV-containing fragments and
the NITEGE’373-containing fragments that are generated in equimolar
amount through the action of aggrecanase, although as a consequence
to different binding motifs to the matrix potentially are released by differ-
ent patterns and amounts. This was compared to the release of other
fragments of aggrecan.
Methods: Aggrecan fragments were measured in the supernatants of
bovine articular cartilage explants stimulated with TNFa/OSM for up to
21 days using a range of immunoassays; (1) 374’ARGSV-containing
fragments (374-G2) were detected using BC3 (ABCAM) and F78 in a
sandwich construction; (2) NITEGE’373-containing fragments were mea-
sured using monoclonal antibody 1H11 recognising the . . .NITEGE′373
neo-epitope in a competition ELISA; (3) 342FFGVG-containing fragments
were measured using AF28 and F78 in a sandwich construction; (4) and
total aggrecan was measured using F78 as both capture and detector
antibody.
Results: As previously reported, aggrecan fragments cleaved by aggre-
canase (374-G2) were released in the early phase of explants culturing,
i.e. peaking at day 7 reaching background levels at day 9, whereas MMP-
related fragments (342-G2) were detected in the late stage, i.e. after
day 15.
Interestingly, aggrecan fragments containing the NITEGE′373 neo-
epitope were released through a different pattern compared to the
other aggrecanase-mediated aggrecan fragments, as a major part of the
NITEGE carrying fragments were detected in the intermediate phase, i.e.
around day 11 after prolonged catabolic stimulation of the explants.
Conclusions: We found that some aggrecan fragments carrying
aggrecanase-mediated neo-epitopes are only released into the super-
natant after prolonged exposure to catabolic cytokines, while others are
released rapidly. Such prolonged exposure will activate MMP-mediated
aggrecan (and type II collagen) degradation, and therefore the data
suggest that these fragments are only released through the action of
both families of proteases. This would be consistent with the G1 domain
participating in the linking to hyaluronic acid in the ECM. This, however,
remains to be investigated further.
